Astellas Pharma and FibroGen have started a Phase II study of ASP1517/FG-4592 to treat anaemia of chronic kidney disease (CKD) in patients on dialysis in Japan.

ASP1517/FG-4592 is the orally administered small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHI).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The candidate has been shown to correct and maintain haemoglobin levels without the need for supplementation with intravenous iron in CKD patients not yet receiving dialysis and in end-stage renal disease patients receiving dialysis.

In late-2013, Astellas expects to conduct an additional Phase II study in Japan of ASP1517/FG-4592 in non-dialysis patients.

The first clinical study in Phase III development of ASP1517/FG-4592 began in December 2012 to support approval in the US and Europe.

See Also:
"In late-2013, Astellas expects to conduct an additional Phase II study in Japan of ASP1517/FG-4592 in non-dialysis patients."

The beginning of Phase II study triggered a $12.5m milestone payment from Astellas, which is responsible for the development cost of ASP1517/FG-4592 in Japan as part of the terms and conditions of an exclusive license agreement with FibroGen.

According to the terms of the deal signed between the parties, FibroGen and Astellas equally share development costs for ASP1517/FG-4592 in the US and in Europe.

In addition to other subsequent events, FibroGen is eligible for milestone payments upon clinical advancement and approvals in Europe and Japan.

FibroGen, which completed Phase II studies of ASP1517/FG-4592 to treat CKD anaemia in the People’s Republic of China, retained rights to its anaemia therapies in North America and South America, remaining parts of Africa and all of Asia Pacific outside of Japan.